Reign Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 4.90 M
as on 17-12-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.40 Cr
as on 17-12-2024
- Revenue %
(FY 2022)
- Profit -307.22%
(FY 2022)
- Ebitda -235.50%
(FY 2022)
- Net Worth -6.48%
(FY 2022)
- Total Assets 175.84%
(FY 2022)
About Reign Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.90 M.
The company currently has active open charges totaling ₹3.40 Cr.
Rameshbhai Naria, Kishan Vaghasiya, Dhirajlal Nariya, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290GJ2019PTC108167
- Company No.
108167
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 May 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Junagadh, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Reign Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rameshbhai Naria  | Director | 15-May-2019 | Current |
| Kishan Vaghasiya | Director | 15-May-2019 | Current |
| Dhirajlal Nariya | Director | 15-May-2019 | Current |
| Nitaben Vaghasiya | Director | 15-May-2019 | Current |
| Jay Nariya | Additional Director | 08-Jan-2024 | Current |
Financial Performance of Reign Pharma.
Reign Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 307.22% decrease in profit. The company's net worth dipped by a decrease of 6.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Reign Pharma?
Unlock access to Reign Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Madhuraam Construction (India) LimitedActive 5 monthsRameshbhai Naria and Dhirajlal Nariya are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Feb 2022 | ₹3.40 Cr | Open |
How Many Employees Work at Reign Pharma?
Unlock and access historical data on people associated with Reign Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reign Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reign Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
